Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryan B Rush

Showing results (1-10 of 55) with videos related to

Pageof 6
Sort By:
Clinical Ophthalmology (Auckland, N.Z.)|August 7, 2023
One-Year Outcomes of Faricimab Treatment for Aflibercept-Resistant Neovascular Age-Related Macular DegenerationRyan B Rush
Clinical Ophthalmology (Auckland, N.Z.)|August 22, 2023
One Year Results of Faricimab for Aflibercept-Resistant Diabetic Macular EdemaRyan B Rush
Korean Journal of Ophthalmology : KJO|August 3, 2013
Contact lens-associated nocardial necrotizing scleritisRyan B Rush
Retinal Cases & Brief Reports|November 13, 2014
Bilateral central retinal artery occlusions and hughes syndromeSaumil Sheth, Ryan B Rush
Clinical Ophthalmology (Auckland, N.Z.)|April 28, 2021
Optical Coherence Tomography-Guided Femtosecond LASIK in the Setting of Corneal ScarringSloan W Rush, Ryan B Rush
Asia-Pacific Journal of Ophthalmology (Philadelphia, Pa.)|December 23, 2015
Ranibizumab Versus Bevacizumab for Neovascular Age-Related Macular Degeneration With an Incomplete Posterior Vitreous DetachmentRyan B Rush, Sloan W Rush
Journal of Ophthalmology|January 24, 2019
Optical Coherence Tomography-Guided Transepithelial Phototherapeutic Keratectomy for Central Corneal Opacity in the Pediatric PopulationSloan W Rush, Ryan B Rush
Clinical Ophthalmology (Auckland, N.Z.)|August 31, 2022
Faricimab for Treatment-Resistant Diabetic Macular EdemaRyan B Rush, Sloan W Rush
Clinical Ophthalmology (Auckland, N.Z.)|June 30, 2021
Pars Plana Vitrectomy with Internal Limiting Membrane Peeling for Treatment-Naïve Diabetic Macular Edema: A Prospective, Uncontrolled Pilot StudyRyan B Rush, Sloan W Rush
Retina (Philadelphia, Pa.)|August 9, 2021
OUTCOMES IN PATIENTS RESUMING INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOLLOWING TREATMENT DELAY DURING THE CORONAVIRUS-19 PANDEMICRyan B Rush, Sloan W Rush
Pageof 6

Showing results (1-10 of 55) with videos related to

Sort By:
Pageof 6
Clinical Ophthalmology (Auckland, N.Z.)|August 7, 2023
One-Year Outcomes of Faricimab Treatment for Aflibercept-Resistant Neovascular Age-Related Macular DegenerationRyan B Rush
Clinical Ophthalmology (Auckland, N.Z.)|August 22, 2023
One Year Results of Faricimab for Aflibercept-Resistant Diabetic Macular EdemaRyan B Rush
Korean Journal of Ophthalmology : KJO|August 3, 2013
Contact lens-associated nocardial necrotizing scleritisRyan B Rush
Retinal Cases & Brief Reports|November 13, 2014
Bilateral central retinal artery occlusions and hughes syndromeSaumil Sheth, Ryan B Rush
Clinical Ophthalmology (Auckland, N.Z.)|April 28, 2021
Optical Coherence Tomography-Guided Femtosecond LASIK in the Setting of Corneal ScarringSloan W Rush, Ryan B Rush
Asia-Pacific Journal of Ophthalmology (Philadelphia, Pa.)|December 23, 2015
Ranibizumab Versus Bevacizumab for Neovascular Age-Related Macular Degeneration With an Incomplete Posterior Vitreous DetachmentRyan B Rush, Sloan W Rush
Journal of Ophthalmology|January 24, 2019
Optical Coherence Tomography-Guided Transepithelial Phototherapeutic Keratectomy for Central Corneal Opacity in the Pediatric PopulationSloan W Rush, Ryan B Rush
Clinical Ophthalmology (Auckland, N.Z.)|August 31, 2022
Faricimab for Treatment-Resistant Diabetic Macular EdemaRyan B Rush, Sloan W Rush
Clinical Ophthalmology (Auckland, N.Z.)|June 30, 2021
Pars Plana Vitrectomy with Internal Limiting Membrane Peeling for Treatment-Naïve Diabetic Macular Edema: A Prospective, Uncontrolled Pilot StudyRyan B Rush, Sloan W Rush
Retina (Philadelphia, Pa.)|August 9, 2021
OUTCOMES IN PATIENTS RESUMING INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOLLOWING TREATMENT DELAY DURING THE CORONAVIRUS-19 PANDEMICRyan B Rush, Sloan W Rush
Pageof 6